Tango Therapeutics (TNGX) Total Liabilities (2020 - 2026)

Tango Therapeutics' Total Liabilities history runs 7 years deep, the most recent figure standing at $44.3 million for Q1 2026.

• On a quarterly basis, Total Liabilities fell 58.82% year-over-year to $44.3 million in Q1 2026; TTM through Mar 2026 was $44.3 million, a 58.82% decrease from a year earlier, with the FY2025 full-year figure at $52.5 million, down 55.11% from the prior year.
• Total Liabilities slipped to $44.3 million in Q1 2026 per TNGX's latest filing, from $52.5 million in the prior quarter.
• Across five years, Total Liabilities topped out at $191.1 million in Q3 2022 and bottomed at $44.3 million in Q1 2026.
• The 5-year median for Total Liabilities is $141.8 million (2024), against an average of $129.2 million.
• Across the five-year window, Total Liabilities surged 2362.75% in 2022 and slumped 59.35% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $187.0 million in 2022, then fell by 20.07% to $149.5 million in 2023, then declined by 21.73% to $117.0 million in 2024, then slumped by 55.11% to $52.5 million in 2025, then slipped by 15.66% to $44.3 million in 2026.
• Per Business Quant, the three latest TNGX Total Liabilities figures stand at $44.3 million (Q1 2026), $52.5 million (Q4 2025), and $50.1 million (Q3 2025).